CONTEXT: Envenomation by the Eastern coral snake is rare but may be associated with significant morbidity. While effective, acquisition of North American Coral Snake Antivenin (NACSAV) is difficult because production was discontinued for many years. OBJECTIVE: The purpose of this study is to characterize coral snake exposures in Florida and determine the effects of varying treatment paradigms on patient outcomes. METHODS: This study is an observational case series of cases received at Florida poison centers. Included cases were Eastern coral snake exposures occurring between January 1, 1998 and October 31, 2010. Excluded cases included those found to be unrelated or those not followed for at least 24 h post envenomation. Case comments were reviewed to obtain data. Comparisons were made between asymptomatic patients receiving empiric antivenom therapy (empiric group) and those asymptomatic patients who received antivenom upon developing signs of systemic envenomation (withhold group). RESULTS: Of the 553 cases identified, 387 were included in the final analysis. According to case comments, 56.3% of patients had no reported systemic symptoms. Most commonly, patients were reported to have pain (40.6%), paresthesias (28.4%), nausea (12.7%), and emesis (11.4%). NACSAV was administered to 252 patients (65%). Of those patients receiving NACSAV, 18.25% were reported to have had an adverse reaction. Patients in the withhold group (n = 106) had significantly fewer minor, moderate, and major outcomes than patients in the empiric group (n = 134, p < 0.01). DISCUSSION: While patients in the withhold group had favorable outcomes compared with those in the empiric group, this strategy cannot be applied to all patients presenting asymptomatic to healthcare facilities due to study limitations. CONCLUSION: Further studies are needed to determine what treatment strategy is most appropriate for asymptomatic patients presenting to healthcare facilities.
CONTEXT: Envenomation by the Eastern coral snake is rare but may be associated with significant morbidity. While effective, acquisition of North American Coral Snake Antivenin (NACSAV) is difficult because production was discontinued for many years. OBJECTIVE: The purpose of this study is to characterize coral snake exposures in Florida and determine the effects of varying treatment paradigms on patient outcomes. METHODS: This study is an observational case series of cases received at Florida poison centers. Included cases were Eastern coral snake exposures occurring between January 1, 1998 and October 31, 2010. Excluded cases included those found to be unrelated or those not followed for at least 24 h post envenomation. Case comments were reviewed to obtain data. Comparisons were made between asymptomatic patients receiving empiric antivenom therapy (empiric group) and those asymptomatic patients who received antivenom upon developing signs of systemic envenomation (withhold group). RESULTS: Of the 553 cases identified, 387 were included in the final analysis. According to case comments, 56.3% of patients had no reported systemic symptoms. Most commonly, patients were reported to have pain (40.6%), paresthesias (28.4%), nausea (12.7%), and emesis (11.4%). NACSAV was administered to 252 patients (65%). Of those patients receiving NACSAV, 18.25% were reported to have had an adverse reaction. Patients in the withhold group (n = 106) had significantly fewer minor, moderate, and major outcomes than patients in the empiric group (n = 134, p < 0.01). DISCUSSION: While patients in the withhold group had favorable outcomes compared with those in the empiric group, this strategy cannot be applied to all patients presenting asymptomatic to healthcare facilities due to study limitations. CONCLUSION: Further studies are needed to determine what treatment strategy is most appropriate for asymptomatic patients presenting to healthcare facilities.
Authors: Jennifer L Parker-Cote; Dorcas P O'Rourke; Kori L Brewer; Kvin Lertpiriyapong; Mohan Punja; Sean P Bush; Susan N Miller; William J Meggs Journal: J Med Toxicol Date: 2015-12
Authors: Daryl C Yang; James Dobson; Chip Cochran; Daniel Dashevsky; Kevin Arbuckle; Melisa Benard; Leslie Boyer; Alejandro Alagón; Iwan Hendrikx; Wayne C Hodgson; Bryan G Fry Journal: Neurotox Res Date: 2017-07-03 Impact factor: 3.911
Authors: Karen Larissa Pereira de Castro; Letícia Lopes-de-Souza; Daysiane de Oliveira; Ricardo Andrez Machado-de-Ávila; Ana Luiza Bittencourt Paiva; Cláudio F de Freitas; Paulo Lee Ho; Carlos Chávez-Olórtegui; Clara Guerra-Duarte Journal: Front Immunol Date: 2019-10-21 Impact factor: 7.561
Authors: Irene Vergara; Erick Y Castillo; Mario E Romero-Piña; Itzel Torres-Viquez; Dayanira Paniagua; Leslie V Boyer; Alejandro Alagón; Luis Alberto Medina Journal: Toxins (Basel) Date: 2016-03-26 Impact factor: 4.546